Key Considerations in Biosimilars Development

被引：0
|
作者：
Donninger, Raymond
Bower, Joe
Kaiser, Raymond
Estdale, Sian
Carlsen, John
机构：
来源：
BIOPHARM INTERNATIONAL | 2012年 / 25卷 / 10期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：37 / 39
页数：3
相关论文
共 50 条
  • [1] Key considerations in the preclinical development of biosimilars
    Bui, Lynne A.
    Hurst, Susan
    Finch, Gregory L.
    Ingram, Beverly
    Jacobs, Ira A.
    Kirchhoff, Carol F.
    Ng, Chee-Keng
    Ryan, Anne M.
    DRUG DISCOVERY TODAY, 2015, 20 : 3 - 15
  • [2] Biosimilars in the Caribbean - Key Considerations
    Cox, S. Dawkins
    WEST INDIAN MEDICAL JOURNAL, 2012, 61 (09): : 849 - 852
  • [3] Clinical considerations for the development of biosimilars in oncology
    Socinski, Mark A.
    Curigliano, Giuseppe
    Jacobs, Ira
    Gumbiner, Barry
    MacDonald, Judith
    Thomas, Dolca
    MABS, 2015, 7 (02) : 286 - 293
  • [4] MANAGEMENT OF BIOSIMILARS: KEY CONSIDERATIONS FOR PHARMACISTS IN PATIENT CARE
    Mohite, N.
    Nayak, R.
    VALUE IN HEALTH, 2018, 21 : S90 - S90
  • [5] BIOSIMILARS ENTRY TO ONCOLOGY PRACTICE: KEY NURSING CONSIDERATIONS
    Zack, Eric
    ONCOLOGY NURSING FORUM, 2019, 46 (02)
  • [6] Biosimilars: Key regulatory considerations and similarity assessment tools
    Kirchhoff, Carol F.
    Wang, Xiao-Zhuo Michelle
    Conlon, Hugh D.
    Anderson, Scott
    Ryan, Anne M.
    Bose, Arindam
    BIOTECHNOLOGY AND BIOENGINEERING, 2017, 114 (12) : 2696 - 2705
  • [7] Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
    Lai, Zhihong
    La Noce, Anna
    RMD OPEN, 2016, 2 (01):
  • [8] Considerations in Pharmacovigilance of Biosimilars
    Sinha, S.
    DRUG SAFETY, 2016, 39 (10) : 1029 - 1029
  • [9] Safety considerations of biosimilars
    McKinnon, Ross
    Ward, Michael
    AUSTRALIAN PRESCRIBER, 2016, 39 (06) : 188 - 189
  • [10] ETHICAL CONSIDERATIONS IN DEVELOPING BIOSIMILARS
    Stanulovic, V
    Zelko, R.
    Kerpel-Fronius, S.
    Gacesa, B.
    Juhasz, M.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 132 - 132
12345